Pulmatrix, Inc.
(NASDAQ : PULM)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Bitcoin & Crypto Movers
Receive our Bitcoin / Cryptocurrency Reports, Free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
PFEPfizer Inc. 3.51%52.430.9%$1363.76m
JNJJohnson & Johnson 1.74%176.970.7%$1352.49m
BMYBristol-Myers Squibb Co. 0.36%76.231.0%$1197.90m
ABBVAbbVie, Inc. -0.53%150.921.9%$1137.44m
MRKMerck & Co., Inc. 1.26%93.250.7%$1136.00m
LLYEli Lilly & Co. 4.49%299.111.1%$892.99m
AZNAstraZeneca Plc 2.59%66.211.0%$517.65m
BHVNBiohaven Pharmaceutical Holding Co. Ltd. 0.65%141.960.0%$458.27m
VERUVeru, Inc. -6.37%13.380.0%$318.66m
NVSNovartis AG 0.86%89.410.2%$251.17m
GSKGlaxoSmithKline Plc 2.23%44.530.2%$243.21m
HZNPHorizon Therapeutics Plc 1.13%90.355.4%$200.40m
NVONovo Nordisk A/S 3.49%107.680.1%$190.60m
SGENSeagen Inc. -2.10%139.645.7%$181.75m
VTRSViatris, Inc. 0.94%11.800.0%$166.13m

Company Profile

Pulmatrix, Inc. is a clinical stage biotechnology company engaged in the discovery and development of novel inhaled therapeutic products for respiratory and other diseases. The firm focuses on the prevention and treatment of respiratory diseases and infections. It offers products based on its proprietary dry powder delivery technology, iSPERSE, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. The company was founded by David Alan Edwards, Mark J. Gabrielson, Alexander M. Klibanov, and Robert S. Langer, Jr. on June 15, 2015 and is headquartered in Lexington, MA.